BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program
NOVEMBER 25, 2014
Vancouver, British Columbia – (November 25, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has received from the Manitoba’s Ministry of Jobs and Economy a funding grant of $50,000 under Commercialization Support for Business (CSB) program which is designed for small and medium-sized businesses.
The CBS program helps Manitoba continue to move forward by supporting product and process commercialization and business development in all sectors and all regions of the province. Specifically, this funding proceeds will be focused on expanding freedom to operate opinions, product packaging and sample runs, cross-validation with third parties and market validation studies.
President and CEO Rashid Ahmed says, “We are very pleased and grateful to the government of Manitoba for this financial support as we realize technology commercialization. BioMark licensed the technology invented by Dr. Daniel Sitar at the University of Manitoba in 2006. The University has an equity stake in BioMark. BioMark is committed to delivering on all the key milestones under the application and our goal is to continue our partnership with investments in Manitoba.”
Press Release BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program (PDF)
Dr. John Yoo Joins BioMark Advisory Team
NOVEMBER 17, 2014
Vancouver, British Columbia – (November 17th, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Dr. John Yoo to its clinical advisory team.
Dr. Yoo is the Professor and Chair, City-Wide Chief, Department of Otolaryngology-Head and Neck Surgery and Professor in the Department of Oncology at the Schulich School of Medicine & Dentistry, Western University; Director of the Head and Neck Oncology & Reconstructive Surgery Program; and the Co-Chair CancerCare Ontario Head and Neck Disease Site Group.
Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome Dr. Yoo’s stature into our company. His achievements in the oncology space will be a major asset to BioMark’s group. Dr. Yoo’s clinical expertise and research experience brings depth and practicality as we position our technology for the patient care setting.”
“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment of lung tumours. BioMark’s technology could be a critically important tool for clinicians” says Dr. Yoo.
Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM – November 17, 2014 (PDF)
BioMark Announces Appointment of Bill Good
November 12, 2014
Vancouver, British Columbia – (November 12th, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Mr. Bill Good to its Advisory Board.
Veteran broadcaster Bill Good has done it all when it comes to media in Canada. Mr. Good spent fifty years on television and radio. For ten years, Mr. Good covered sports with CBC including Olympic and Commonwealth Games as well as Hockey night in Canada and co-hosted the famous Canada-Soviet hockey summit in 1972. Mr. Good left sports broadcasting in the late seventies and spent thirty years anchoring flagship early evening news at CBC, BCTV, and CTV all the while hosting the top rated Bill Good Show on CKNW.
BioMark Expands Phase 3 Clinical Trials
NOVEMBER 5, 2014
Vancouver, British Columbia – (November 5, 2014)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that BioMark has expanded its Phase 3 cancer screening clinical trials to include The National Institute of Cancer Research and Hospital in Bangladesh. The clinical trials are in the process of being registered with both clinicaltrials.gov and the World Health Organization (WHO).
BioMark anticipates completing 50% of the 340 patient Phase 3 clinical trial by the first quarter of 2015. Following a successful completion of the clinical trial and regulatory health approval, BioMark will commence marketing its proprietary technologies in key global markets.
Rashid Ahmed , President & CEO, states: “This is a significant achievement for BioMark. Strong research collaborators such as The National Institute of Cancer Research and Hospital in Bangladesh, in addition to long-term partners such as St-Boniface Hospital Research, CancerCare Manitoba, Surrey Memorial Hospital, have been instrumental in moving our cancer diagnostic technology forward. We look forward to completing our trials in 2015 and to offer diagnostic options that can be used solo or to complement existing cancer detection and treatment technologies.”
BioMark Approved Listing and Commences Trading on the CSE
NOVEMBER 3, 2014
Vancouver, B.C. – (November 3, 2014) BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) is pleased to announce that it has received approval to list its Common Shares for trading on the Canadian Securities Exchange (“CSE”), and that its Common Shares have commenced trading as of the opening of market, today, November 3, 2014, under the trading symbol “BUX”.
Follow this link to the CSE: <a href=”http://www.thecse.com/CNSX/Securities/Life-Sciences/BioMark-Diagnostics-Inc.aspx” target=”_blank”>http://www.thecse.com/CNSX/Securities/Life-Sciences/BioMark-Diagnostics-Inc.aspx</a>
BioMark Raman SenSers Product Launch at Strategies on Biophotonics Boston September 9-11 2014
BioMark is proud to announce the launch of its first generation Raman SERS at the first Strategies in Biophotonics conference held in Boston. The technology platform was developed by Dr. Reuven and Dr. Hof from the University of Victoria, BioMark and Innovative Photonics Solutions.
Jim Elliott, the Principal Engineer is shown below at the show along with the team from Innovative Photonics Solutions. The trio of experts are working on new developments for BioMark’s next generation of Raman analytical systems. BioMark is in negotiations with multiple partners both locally and internationally for product sales and placement later in 2014 or early 2015.